XML 44 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Supplemental Financial Information (Details)
shares in Thousands, $ in Millions
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 27, 2015
shares
Apr. 30, 2015
shares
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Jun. 30, 2015
USD ($)
shares
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Feb. 17, 2016
Feb. 16, 2016
Dec. 31, 2015
USD ($)
Net earnings                    
Earnings from continuing operations allocated to common shares     $ 597   $ 783 $ 652 $ 1,300      
Net earnings allocated to common shares     612   780 927 3,100      
Gain on sale of Mylan shares             207      
Proceeds from the sale of Mylan shares             2,290      
Post-employment Obligations and Other Long-term Liabilities:                    
Noncash impact of tax benefits from resolution of prior year tax positions           410        
Non-cash impact of tax expense associated with the gain on the sale of businesses             $ 1,100      
Investments                    
Investments     $ 3,339     3,339       $ 4,041
Currency exchange rates                    
Foreign currency loss on remeasurement           477        
Mylan                    
Net earnings                    
Gain on sale of Mylan shares         207          
Number of shares in investment sold | shares   40,250                
Proceeds from the sale of Mylan shares         $ 2,290          
Investments                    
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc | shares   110,000                
Mylan NV                    
Net earnings                    
Remaining ownership interest ( as percentage)   14.00%     14.00%   14.00%      
Venezuela                    
Post-employment Obligations and Other Long-term Liabilities:                    
Cash impact from foreign currency loss           $ 410        
Investments                    
Abbott's total net assets from Venezuelan operations (as a percent)     0.10%     0.10%        
Currency exchange rates                    
Foreign currency loss on remeasurement       $ 477   $ 477        
Venezuelan bolivars                    
Currency exchange rates                    
Official rate to U.S. dollar                   6.3
CENCOEX                    
Currency exchange rates                    
Official rate to U.S. dollar                   6.3
SICAD                    
Currency exchange rates                    
Official rate to U.S. dollar                   13.5
SIMADI                    
Currency exchange rates                    
Official rate to U.S. dollar                   200
DIPRO                    
Currency exchange rates                    
Official rate to U.S. dollar               10 6.3  
DICOM                    
Currency exchange rates                    
Official rate to U.S. dollar       263            
Defined Benefit Plans                    
Post-employment Obligations and Other Long-term Liabilities:                    
Company contributions           524 $ 547      
Medical and Dental Plans                    
Post-employment Obligations and Other Long-term Liabilities:                    
Company contributions           9 $ 24      
Equity securities                    
Investments                    
Investments     $ 3,288     3,288       $ 4,014
Other,                    
Investments                    
Investments     $ 51     51       $ 27
Developed markets branded generics pharmaceuticals business                    
Post-employment Obligations and Other Long-term Liabilities:                    
Cash impact of tax benefits from resolution of prior year tax positions           $ 140        
Developed markets branded generics pharmaceuticals business | Mylan                    
Net earnings                    
Gain on sale of Mylan shares         $ 207          
Decrease in fair value of contingent consideration         79          
Proceeds from the sale of Mylan shares         $ 2,290          
Investments                    
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc | shares 110,000                  
Developed markets branded generics pharmaceuticals business | Mylan NV                    
Net earnings                    
Number of shares in investment sold | shares         40,300          
Investments                    
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc | shares         110,000          
Percentage of shares held before sale of generics pharmaceuticals business to Mylan Inc         22.00%